Double-activation of mitochondrial permeability transition pore opening via calcium overload and reactive oxygen species for cancer therapy | Journal of Nanobiotechnology

[ad_1]

Synthesis and characterization of O2-FeCOF@CaCO3@FA NPs

The well-dispersed spherical FeCOF was simply synthesized by using acetic acid as catalyst at room temperature (Fig. 1a and Additional file 1: Figure S1). FeCOF@CaCO3 was prepared via gas diffusion method. As illustrated in Fig. 1b, in a closed vacuum, the CO2 and NH3 gases produced by the natural decomposition of NH4HCO3 would continuously diffuse into the mixed solution containing Ca2+. Simultaneously CO32− was provided into the alkaline solution to trigger the formation of CaCO3 [43]. Thin nanosheets of CaCO3 could be observed on the surface of FeCOF by transmission electron microscopy (TEM, Fig. 1c) and scanning electron microscopy (SEM, Additional file 1: Figure S2). Elemental mapping analysis showed that C, O, N, Fe and Ca elements of FCCF nanoparticles were homogeneously distributed (Fig. 1d). X-ray photoelectron spectroscopy (XPS) was used to analyse Ca element signal of FeCOF@CaCO3. The two peaks located at 347.2 eV and 350.7 eV for 2p1/2 and 2p3/2, respectively, were considered as the characteristic peaks of CaCO3 (Fig. S3) [44]. Powder Xray diffraction (PXRD) patterns have confirmed the excellent crystallinity of FeCOF and FeCOF@CaCO3 (Additional file 1: Figure S4) [37, 45]. The surface area and pore volume of FeCOF and FeCOF@CaCO3 were 1380.170 m2/g, 1.292 cc/g and 373.731 m2/g, 0.305 cc/g. Compared with FeCOF, FeCOF@CaCO3 showed decreased Brunauer–Emmett–Teller (BET) surface area and pore volume, confirming the successful coating of CaCO3 (Additional file 1: Figure S5). Then FA was modified on the surface of FeCOF@CaCO3 to obtain the final FeCOF@CaCO3@FA (FCCF) nanoparticles (Fig. 1e). In the FTIR spectra of FeCOF@CaCO3, the peak at 1592 cm−1 (peak 1) was ascribed to the vibration of -NH2 and the characteristic peak at 712 cm−1 (peak 2) belonged to carbonate. In the FTIR spectra of FCCF, the characteristic peaks at ~ 1573 (peak 3) and 1647 cm−1 (peak 4) have been characterized as the stretching vibration mode of secondary amide bonds (C = O-NH), further demonstrating the successful synthesis of FCCF (Fig. 1f), further demonstrating the successful synthesis of FCCF [46, 47]. UV–visible (UV-vis) absorption spectrum of FCCF showed that there was a broad absorption between 400 and 700 nm, which was similar to the absorption of FeCOF nanoparticles. Meanwhile, the strong absorbance peak centered at 281 nm of FCCF validated the integration of FA into the nanosystem (Fig. 1g). TEM and Dynamic light scattering (DLS) measurements showed that the mean size of FCCF was about 230 nm (Additional file 1: Figure S6 and Table S1), slightly larger than that of FeCOF and FeCOF@CaCO3 nanoparticles. In addition, the successful synthesis of FCCF could also be proved by the zeta potential changes (Additional file 1: Figure S7). The post-modification of FA could enhance the bio-compatible and tumor targeting abilites of FCCF. As shown in Additional file 1: Figure S8, FCCF composite were uniformly dispersed in water, phosphate buffered saline (PBS) and cell culture medium (containing 10% serum) for 7 days without any aggregation at room temperature. The morphology of the nanocomposite had no change even after incubation in water for a week. These results verified the good stability of FCCF for potential clinical applications.

Fig. 1
figure 1

a TEM image of FeCOF. b Schematic diagram of synthesis method of FeCOF@CaCO3. c TEM image and (d) elemental mapping of FeCOF@CaCO3. e TEM image of FCCF. f FTIR spectra of FA, FeCOF@CaCO3 and FCCF. g UV–vis absorption spectra of FeCOF, FeCOF@CaCO3, FA and FCCF

In vitro release study

In order to verify TME-activated bio-decomposition abilities of FCCF nanoparticles, various measurements were conducted. FCCF and FeCOF nanoparticles were dispersed in PBS with different pH to observe the morphology changes at different time points. As shown in Additional file 1: Figure S9 and S10, FCCF nanoparticles showed no change on size and structure when dispersed in PBS at pH 7.4. In contrast, FCCF nanoparticles dissociated in PBS with low pH (6.5 and 5.5), resulting in the nanosheet like morphology of the surface was largely lost after 1 h. Meanwhile, the hydrodynamic sizes of nanoparticles for time-dependent changes were monitored by DLS at different pH values. The hydrated particle of FCCF nanoparticles at pH 6.5 and 5.5 for 1 h were around 180 nm and 100 nm, respectively (Fig. 2a). Then, the time-dependent release profiles of Ca2+ were further assessed in buffers with various pH values. As shown in Fig. 2b, the low pH condition (5.5) led to a sustained release of Ca2+, with 89.2% Ca2+ being released from FeCOF carrier. However, only about 66.4% Ca2+ was released after being incubated at pH 6.5. The above results strongly proved that FCCF exhibited promising pH-responsive Ca2+ release ability.

Fig. 2
figure 2

a Time-dependent DLS-measured size changes of FCCF under different pH conditions (pH 7.4, 6.5 and 5.5). b Time-dependent release of Ca2+ from the FCCF dispersed in pH 7.4, 6.5 and 5.5 buffers. c Time-dependent dissolved oxygen generation induced by O2-COF in deoxidized PBS. d Time-dependent dissolved oxygen generation induced by OFCCF in deoxidized PBS (pH 6.5). e UV–Vis absorption of DPBF after 650 nm laser irradiation with H2O, COF (100 μg mL−1) and OFCCF (100 μg mL−1, pH 6.5). f ESR spectra of FCCF and OFCCF under 650 nm laser irradiation (0.72 W cm−2, 10 min)

The release of Ca2+ further facilitated oxygen diffusion to meet the increased oxygen demand in hypoxic tumor. O2 releasing ability of OFCCF and O2-COF in deoxidized PBS buffer was illustrated in Fig. 2c, d. The storaged O2 of OFCCF and O2-COF were released under a hypoxic environment by passive transportation. However, the released O2 from OFCCF was approximately twofold as that from O2-COF, which was attributed to the affinity of Fe2+ with O2. Moreover, the bubbles produce in the OFCCF solution also demonstrated the specific oxygen release behavior of Additional file 1: Figure S11. The ROS generation ability of OFCCF was investigated by 1,3-diphenylisobenzofuran (DPBF). Compared with free DPBF, COF showed effective time-dependent ROS production under 650 nm (0.72 W cm−2) laser irradiation, which was attributed to its strong absorption (Fig. 1g). Moreover, the released O2 could enhance the production of ROS (Fig. 2e). Next, electron spin resonance (ESR) with 2,2,6,6-tetramethyl-4-piperidinol (TEMP) as singlet 1O2 trapping agent was used for detecting 1O2 generation. 1O2 signal (1:1:1) was observed for OFCCF under 650 nm laser irradiation, which was stronger than that of FCCF (Fig. 2f). Overall, OFCCF with excellent 1O2 generation ability could effectively overcome tumor hypoxia and enhance PDT effect for breast cancer.

Cancer cell death induced by calcium overload

Next, the cellular internalization of rhodamine B (RhB)-labelled FCCF nanoparticles was examined in murine 4T1 breast cancer cells. Figure 3a indicated the time-dependent internalization process of FCCF nanoparticles, as evidenced by the colocalization of red fluorescence for RhB-labelled FCCF nanoparticles and the green fluorescence for LysoTracker. These results improved that FCCF nanoparticles could be effectively uptaken by 4T1 cells, which was beneficial to killing tumor cells. Within acidic lysosomes, OFCCF nanoparticles could release Ca2+ rapidly, which led to a direct increase of osmotic pressure and influx of Cl and H2O molecules to result in proton spongeeffect [21, 46, 47]. Simultaneously, under 650 nm laser irradiation, a large number of 1O2 were produced by the nanoparticles, causing the destruction of lysosome membrane structure to favor the endosomal escape of nanoparticles. Then, intracellular Ca2+ concentration was monitored using the calcium indicator dye Fluo-4. Weak green fluorescence was observed in PBS group and L group of 4T1 cells. In contrast, compared with other groups, the intracellular Ca2+ concentration in the OFCCF + group was highest (Additional file 1: Figure S12). In addition, mitochondrial Ca2+ concentrations were quantified using the calcium indicator dye Rhod2. The FCCF, COF + and CaCO3 groups exhibited weak red luminescence, while the group treated with OFCCF + exhibited strong intracellular luminescence, indicating Ca2+ influx of 4T1 cells could be better activated in the presence of ROS (Additional file 1: Figure S13). Via Calcium Colorimetric assay, the OFCCF + displayed the highest intracellular Ca2+ concentration as 19.4 μg/mL, indicating an obvious Ca2+ overloading (> 3.2 μg/mL in PBS group) (Additional file 1: Figure S14). The release of Ca2+ and the hypoxic tumor microenvironment would trigger the free diffusion of oxygen by passive-transport. The O2 probe [Ru(dpp)3]Cl2 (RDPP) which is prone to luminescence quenching by oxygen was used to monitor cellular O2-evolving. As shown in Fig. 3b, the green fluorescence intensity of OFCCF group decreased obviously under hypoxic conditions, while the green fluorescence was observed for L treated and FCCF treated groups. Then, quantitative analysis of dynamic changes of intracellular oxygen via calculating average intensity by ImageJ software. The green fluorescence intensity of 4T1 cells treated with OFCCF + was 22%, which was about three times lower than the other three groups (Additional file 1: Figure S15). Meanwhile, as the expression of HIF1α protein is upregulated under a hypoxic condition, the degree of hypoxia can be further assessed according to the level of HIF1α. The OFCCF treated 4T1 cells exhibited a low expression of HIF1α by western blotting (WB) analysis (Fig. 3c and Additional file 1: Figure S16). These results suggested that OFCCF could release O2 to alleviate the hypoxic state of tumor microenvironment. The enhance of ROS generation by OFCCF-mediated O2 was proved by intracellular 1O2 test with 2ʹ,7ʹ-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence as a probe. As shown in Additional file 1: Figure S17, a comparative intensity of green fluorescence was observed under hypoxia and normoxia conditions, suggesting the key role of oxygen release in PDT.

Fig. 3
figure 3

a The images of 4T1 cells incubated with FCCF recorded at different time points. b [Ru(dpp)3]Cl2 was used as probe to detect O2 generation after treatment with: (1) PBS + , (2) FCCF, (3) FCCF + and (4) OFCCF + . c Western blot analysis of HIF-1α expression of 4T1 cells. d Mitochondrial distribution and mitochondrial membrane potential images of 4T1 cells after different treatments. e Bio-TEM images of 4T1 cells after different treatments. Red arrows exhibit the location of destructed mitochondria in 4T1 cells

Ca2+ overload and 1O2 can cause the conformational changes of MPTP structural proteins, which allows substances with a molecular weight greater than 1500 to pass through the inner mitochondrial membrane (IMM) by non-selectively way. The entered substances result in the collapse of mitochondrial membrane potential (MMP), the uncoupling of oxidative phosphorylation process and the disturbance of ATP production, consequently causing mitochondria function impairment [16]. Therefore, we used commercial Calcein-AM or Calcein-AM + CoCl2 dye as a fluorescence indicator to evaluate whether OFCCF was able to induce the continuous activation of MPTP. Upon treatment with FCCF or COF + , green fluorescence was observed. In contrast, no green fluorescence was detected for OFCCF group. However, upon receiving simultaneous exposure of OFCCF + and 5 µM uncoupling agent (CCCP), the 4T1 cells exhibited green fluorescence signal (Additional file 1: Figure S18), suggesting the critical role of Ca2+ overloading to activate MPTP opening. Next, to reveal the degree of mitochondrial damage induced by enhanced mitochondrial Ca2+ overload, the mitochondrial membrane potential of 4T1 cells was evaluated using commercial JC-1 dye. The OFCCF + group showed strong green fluorescence signal, in marked contrast to the strong red fluorescence observed in other groups. Subsequently, intracellular mitochondrial distribution was detected by staining with Mito Tracker® Red CMXRos. As expected, the fewest mitochondria damage were detected in the OFCCF + group (Fig. 3d and Additional file 1: Figure S19). Finally, biological transmission electron microscopy (Bio-TEM) was used to visualize changes in their mitochondria (Fig. 3e). The 4T1 cells treated with FCCF, COF + or FCCF + exhibited only mild mitochondrial destruction, whereas OFCCF + caused the most obvious mitochondrial destruction, with visible swelling and cavitation of mitochondria. These results confirm that OFCCF + can cause severe mitochondrial damage through mitochondrial Ca2+ overload. In addition, the intracellular ATP content treated with OFCCF + decreased significantly in comparison to other five groups, which was partially produced via the oxidative phosphorylation inside the mitochondria (Additional file 1: Figure S20). All of the results revealed that the increased intracellular Ca2+ and production of 1O2 induced by OFCCF + could cause mitochondrial dysfunction.

The collapse of MMP induces a series of pathological changes in mitochondria, resulting in the release of Cyt c from mitochondrial matrix into cytoplasm. And Cyt c and apoptotic protein activator-1 (Apaf-1) can form a composite to trigger cell apoptosis [48]. To confirm this principle, the expression of apoptosis-related proteins was investigated by western blotting. As illustrated in the Fig. 4a, the expression levels of Cyt c and caspase 3 increased after the treatment of OFCCF + in comparison to the PBS, FCCF and FCCF + groups. By contrast, the protein levels of Bcl-2 in 4T1 cells were markedly down-regulated after OFCCF + treatment. Detailed quantitative results of WB were gathered in Fig. 4b. In addition, the release of Apaf-1 from the supernatant of 4T1 cells was measured by enzyme-linked immunosorbent assay (ELISA). As shown in Fig. 4c, the OFCCF + treatment elevated the release of Apaf-1 effectively. The above results indicated that mitochondrial-mediated apoptotic pathway was activated after the mitochondrial Ca2+ overload and production of 1O2.

Fig. 4
figure 4

a Western blot analysis Cyt c, Bcl-2 and Caspase 3 expression of 4T1 cells. b Quantitative analysis of Cyt c, Bcl-2 and Caspase 3 expression. c Apaf-1 level of cell supernatant after various treatments. P values were calculated by one-way analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data were represented as mean ± SD (n = 6). d Cytotoxicity profiles of 4T1 cells treated with: (1) PBS, (2) L, (3) FCCF, (4) COF + , (5) FCCF + and (6) OFCCF + . P values were calculated by one-way analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data were represented as mean ± SD (n = 4). e Schematic diagram of mitochondrial damage induced by bidirectional activation of MPTP opening by Ca2+ and 1O2

Then, the cytotoxic effect of COF and FCCF nanoparticles towards L929 fibroblast cells and 4T1 cells was evaluated using the standard methyl thiazolyl tetrazolium assay (MTT). L929 cells were treated with various concentrations of COF and FCCF nanoparticles within 24 and 48 h, the survival rate maintained above 80%. The proliferation ability of L929 cells treated with OFCC + and OFCCF + decreased slightly (Additional file 1: Figure S21). These results demonstrated the biosafety and biocompatibility of the nanoparticles. To further investigate the therapeutic effect of Ca2+ overload/PDT, the anti-cancer effect of OFCCF under hypoxic and normoxic environment was tested. Upon 650 nm laser irradiation, the cytotoxicity of FCCF + under normoxic environment was greatly enhanced than that of FCCF + under the hypoxic environment. Notably, the hypoxia condition had significant effect on the cancer cell killing effect of FCCF + -treated group. While the survival rate of OFCCF + treated group was almost the same as the group under hypoxia condition owing to the oxygen-carrying properties of FeCOF (Fig. 4d). Moreover, from the live/dead cell staining test, we observed that most cells remained alive after the treatment of PBS and L. By contrast, the OFCCF + treated group showed a large number of dead cells in the Additional file 1: Figure S22. This result was consistent with the flow experimental results (Additional file 1: Figure S23). Collectively, all above results reveal that OFCCF is a promising candidate to induce cancer cell death through Ca2+ overload and 1O2 co-activating MPTP opening (Fig. 4e).

In vivo therapeutic effect investigation

The in vivo therapeutic efficacy of OFCCF was further examined by a 4T1 breast tumor model. The tumor-bearing mice were randomly divided into six groups for the different treatments: (1) PBS, (2) 650 nm laser irradiation (L), (3) FCCF, (4) COF + , (5) FCCF + and (6) OFCCF + . After intravenously injection with nanocomposites (100 μg mL−1) for 12 h, the mice were treated with 650 nm laser irradiation (0.72 W cm−2) for 5 min (Fig. 5a). The obtained nanocomposites had no side effect on the body weight of mice, suggesting the good biosafety of the nanocomposites (Additional file 1: Figure S24). Tumor suppression assessments showed a considerable suppression effect on the tumors of FCCF + group and OFCCF + group in comparison with other four groups. (Fig. 5b). This result was consistent with the pictures of mice tumors and tumor weight (Fig. 5c and Additional file 1: Figure S25). Furthermore, hematoxylin and eosin (H&E) staining results were shown in Fig. 5d, obvious cell necrosis and apoptosis could be observed in OFCCF + group. From the TUNEL staining results, the green signal represented that cells apoptosis was appeared after the treatment of OFCCF + . Meanwhile, the typical morphology of apoptotic cells was detected in caspase 3 staining assay. Finally, to better assess the effect of this synergistic therapy, we next examined the lung metastasis of 4T1 tumor-bearing mice after various treatments. H&E staining and imaging of lung sections confirmed that OFCCF + effectively suppressed tumor metastasis (Additional file 1: Figure S26).

Fig. 5
figure 5

a Schematic description of the establishment of 4T1 tumor model and therapeutic outcome. b The relative tumor volume of mice in different groups after treatment. P values were calculated by one-way analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data were represented as mean ± SD (n = 6). c Tumor weight in different groups after treatment. P values were calculated by one-way analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data were represented as mean ± SD (n = 6). d H&E, TUNEL and Caspase 3 staining of tumor collected from mice after various treatments

Moreover, the therapeutic efficiency of OFCCF + was further evaluated (Fig. 6a). To study the bio-distribution of FCCF,FCCF was injected intravenously into 4T1-tumor-bearing mice and Fe content was tracked by inductively coupled plasma mass spectrometry (ICP-MS). As shown in Fig. 6b, nanoparticles preferentially accumulated at the tumor site due to the specific binding of FA with breast cancer folate receptors, showing the highest content at 12 h after injection. Apart from tumors, the nanoparticles were also accumulated in liver and kidney. As shown in Fig. 6c, the content of FCCF nanoparticles in liver and kidney decreased gradually, confirming that they could be metabolized from the body through the renal-urinary clearance system within one week. The tumor accumulation and clearance performance of FCCF provides enormous potential for effective and safe cancer treatment. Furthermore, the bio-degradation performance of nanoparticles triggered by TME was further studied. After the PBS, FCCF and OFCCF was injected intravenously into 4T1-tumor-bearing mice for 12 h, respectively, the Ca2+ released from nanoparticles accumulated in tumor owing to the acidic condition of TME. As we expected, the Ca2+ content in the tumors significantly increased after being treated with OFCCF + in comparison to FCCF and FCCF + groups. It is further revealed that the production of ROS could promote the aggregation of Ca2+, resulting in the apoptosis caused by Ca2+ overload (Fig. 6d). Next, the possible mechanism of Ca2+ overload-induced apoptosis was explored by ELISA and western blotting to determine the content of apoptosis-related proteins of tumours. Once Cyt c is released from the mitochondria, it can couple with Apaf-1 to form the apoptosome. As illustrated in Fig. 6e, the upregulation of Apaf-1 confirmed the formation of apoptosome. Besides, the expression levels of Cyt c, Bcl-2 and caspase 3 were further detected by western blotting. As illustrated in the Fig. 6f, compared with the control groups (PBS, FCCF and FCCF +), Cyt c and caspase 3 expressions levels increased significantly but the protein levels of Bcl-2 decreased after OFCCF + treatment. The quantitative analysis of western blotting was shown in Additional file 1: Figure S27. Compared with the other groups, the ATP level of OFCCF + group decreased significantly owing to Ca2+ overload in mitochondria, which would damage the energy supply of cancer cells (Additional file 1: Figure S28). To identify the ability of OFCCF to relieve tumor hypoxia, mice tumors were obtained for HIF-1α (green) staining assay after being injected with the nanoparticles for 10 h. As illustrated in the Fig. 6g, the intensity of fluorescence was hardly visible in OFCCF + group. For ROS staining assay, OFCCF + group showed the strongest DCFH-DA fluorescence signals in tumor slices, which was consistent with the HIF-1α (green) staining assay results. Meanwhile, the remission of tumor hypoxia was further verified by down-regulation of HIF-1α expression level, indicating that released oxygen could relieve intratumoral hypoxia and enhance production of ROS (Additional file 1: Figure S29).

Fig. 6
figure 6

a Schematic illustration of OFCCF-based Ca2+ release and production 1O2 activation of MPTP opening inhibits tumor growth. b The biodistribution of Fe in main tissues and tumor (c) and feces in different times after intravenously injecting with OFCCF into 4T1-tumor-bearing. Data were represented as mean ± SD (n = 3). d The biodistribution of Ca in tumor after various treatments at 12 h intravenously injecting into 4T1-tumor-bearing. Data were represented as mean ± SD (n = 3). e Apaf-1 level of tumor supernatant after various treatments. P values were calculated by one-way analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Data were represented as mean ± SD (n = 3). f Western blot analysis Cyt c, Bcl-2 and Caspase 3 expression of tumor. g HIF-1α and DCFH-DA staining of tumor collected from mice after various treatments

To assess the potential therapeutic toxicity of FCCF, a systemic toxicity study was performed. The physiological pathology of main organs were analysed by H&E staining. No significant pathological changes in major organs (heart, liver, kidney lung, and spleen) were observed after different treatments (Additional file 1: Figure S30), suggesting the excellent biosafety of the nanocomposite in vivo. Meanwhile, biochemical analysis further confirmed that OFCCF + had low toxicity (Additional file 1: Figure S31).

[ad_2]

Source link

Leave a Reply

Your email address will not be published.